<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023710</url>
  </required_header>
  <id_info>
    <org_study_id>BCH-MM-131101</org_study_id>
    <nct_id>NCT02023710</nct_id>
  </id_info>
  <brief_title>Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma</brief_title>
  <official_title>A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment
      for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in
      patients with previously untreated metastatic mucosal melanoma to characterize the efficacy
      and safety of bevacizumab when combined with carboplatin plus paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucosal melanoma is rare and associated with extremely poor prognosis.It is the second most
      common subtype in Asians.No effective treatment for advanced mucosal melanoma
      patients.Malignant melanoma is a highly vascular tumor in which vascular endothelial growth
      factor(VEGF) is strongly expressed and seems to play an important role in disease
      progression.A randomized phase II study evaluated the activity of Bevacizumab in combination
      with carboplatin plus paclitaxel(CPB arm) in patients with previously untreated advanced
      melanoma.Overall response rates was 25.5%,median overall survival time(OS) was 12.3 months in
      the CPB arm. Investigators conducted a randomized phase II study in patients with previously
      untreated metastatic mucosal melanoma to characterize the efficacy and safety of bevacizumab
      when combined with carboplatin plus paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress-free survival(PFS)</measure>
    <time_frame>From randomization up to 144 weeks</time_frame>
    <description>Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event(AE)</measure>
    <time_frame>From randomization up to144 weeks</time_frame>
    <description>Any events,no matter related to interventions,occur during the period from the enrollment to death or 30 days after withdrawal from the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>Up to 144 weeks</time_frame>
    <description>Overall survival was defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>BEV plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)</description>
    <arm_group_label>BEV plus Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <other_name>Taxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle</description>
    <arm_group_label>BEV plus Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <other_name>CBP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)</description>
    <arm_group_label>BEV plus Chemotherapy</arm_group_label>
    <other_name>BEV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed mucosal melanoma with metastases and has no received any
             systemic treatment.

          2. ECOG performance status 0, 1

          3. Estimated life expectancy of 12 weeks or greater

          4. Age 18 years or older, male or female

          5. At least one measurable site (diameter≥1cm) of disease (RECIST 1.1).

          6. Adequate organ function

          7. Without symptoms of brain metastases and stable in neuro-functions.

          8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures

        Exclusion Criteria:

          1. Mutations in C-KIT or BRAF-V600E, asked for other target treatments

          2. Pregnant or lactation women

          3. Acute infections without control.

          4. Heart disease history, cardiac function class≥NYHA II.

          5. HIV positive or chronic HBV/HCV in active stage.

          6. Brain metastases or primary tumor with positive symptoms

          7. Need anti-epileptic treatments

          8. Organ transplantation history

          9. Hemorrhagic tendency or related history

         10. Renal dialysis patients

         11. Diagnosis of any second malignancy within the last 3 years, except for adequately
             treated.

         12. Current treatment on another clinical trial

         13. The other improper situations which investigator judged.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinan Sheng, MD</last_name>
    <phone>0086-10-88196951</phone>
    <email>doctor_sheng@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoshi Zhang, MD</last_name>
      <phone>0086-20-87343088</phone>
      <email>zxs617@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoshi Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinan Sheng, MD</last_name>
      <phone>0086-10-88196951</phone>
      <email>doctor_sheng@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yunan Tumor Hospital</name>
      <address>
        <city>Kunming</city>
        <zip>650106</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Song, MD</last_name>
      <phone>0086-871-8185656</phone>
      <email>songxin68@126.com</email>
    </contact>
    <investigator>
      <last_name>Xin Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan 1;30(1):34-41. doi: 10.1200/JCO.2011.34.6270. Epub 2011 Nov 28.</citation>
    <PMID>22124101</PMID>
  </reference>
  <reference>
    <citation>Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011 Feb 25;11:85. doi: 10.1186/1471-2407-11-85.</citation>
    <PMID>21349197</PMID>
  </reference>
  <reference>
    <citation>Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, Li S, Kong Y, Tang B, Guo J. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013 Aug 15;19(16):4488-98. doi: 10.1158/1078-0432.CCR-13-0739. Epub 2013 Jul 5.</citation>
    <PMID>23833309</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Guo</investigator_full_name>
    <investigator_title>Director of department of renal cancer and melanoma</investigator_title>
  </responsible_party>
  <keyword>mucosal melanoma</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

